Substrate reduction therapy
The glycosphingolipidoses are a family of storage diseases that arise due to incomplete catabolism of glycosphingolipids (GSLs) in the lysosome (Wraith, 2002). The majority are autosomal recessive disorders and result from mutations in the genes that encode the catabolic enzymes of the lysosome (Win...
Main Authors: | Platt, F, Butters, T |
---|---|
Format: | Book section |
Published: |
Springer US
2007
|
Similar Items
-
Substrate reduction therapy in mouse models of the glycosphingolipidoses.
by: Platt, F, et al.
Published: (2003) -
Substrate reduction therapy.
by: Platt, F, et al.
Published: (2008) -
Substrate reduction therapy for glycosphingolipid storage disorders.
by: Lachmann, R, et al.
Published: (2001) -
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
by: Andersson, U, et al.
Published: (2004) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
by: Platt, F, et al.
Published: (2000)